The content is available as a PDF (43.4 KB).
Biblografía
- 1.Molitch M.E. Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am. 1992;21(4):877–901. [PubMed] [Google Scholar]
- 2.Kelley S.R., Kamal T.J., Molitch M.E. Mechanism of verapamil calcium channel blockade induced hyperprolactinemia. Am J Physiol. 1996;270(Pt 1):96–100. doi: 10.1152/ajpendo.1996.270.1.E96. [DOI] [PubMed] [Google Scholar]
- 3.Dombrowski R.C., Romeo J.H., Aron D.C. Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma. Ann Pharmacother. 1995;29(10):999–1001. doi: 10.1177/106002809502901009. [DOI] [PubMed] [Google Scholar]
- 4.Romeo J.H., Dombrowski R., Kwak Y.S., Fuehrer S., Aron D.C. Hyperprolactinaemia and verapamil: prevalence and potential association with hypogonadism in men. Clin Endocrinol Oxf. 1996;45(5):571–575. doi: 10.1046/j.1365-2265.1996.00859.x. [DOI] [PubMed] [Google Scholar]
- 5.Knoepfelmacher M., Villares S.M., Nicolau W., Germek O.O., Lerario A.C., Wajchenberg B.L. Calcium and prolactin secretion in humans: effects of the channel blocker, verapamil, in the spontaneous and drug-induced hyperprolactinemia. Horm Metab Res. 1994;26(10):481–485. doi: 10.1055/s-2007-1001738. [DOI] [PubMed] [Google Scholar]
- 6.Barbaro D., Faggionato F., Pallini S., Carnesecchi C., Palla A., Bombara M. Verapamil acute administration: a new dynamic test in hyperprolactinemic states. Metabolism. 1999;48(11):1351–1356. doi: 10.1016/s0026-0495(99)90142-7. [DOI] [PubMed] [Google Scholar]
- 7.Lockett T. Radcliffe Medical Press; Oxford: 1997. Evidence-based and costeffective medicine for the uninitiated. [Google Scholar]